Case number 2017-1798
Sumitomo Dainippon Pharma Co. v. Emcure Pharmaceuticals > Documents
| Date Field | Doc. No. | Description (Pages) |
|---|---|---|
| Apr 23, 2021 | 0 | SUMITOMO DAINIPPON PHARMA CO. v. EMCURE PHARMACEUTICALS [OPINION] [precedential] (0) |
| May 23, 2018 | 59 | Mandate issued to the United States District Court for the District of New Jersey. Service as of this date by the Clerk of Court. [523786] [17-1798, 17-1799, 17-1800] [SJ] [Entered: 05/23/2018 08:40 AM] (2) |
| Apr 16, 2018 | 58 | OPINION and JUDGMENT filed. The judgment or decision is: Affirmed. (Precedential Opinion). (For the Court: Moore, Circuit Judge; Mayer, Circuit Judge and Stoll, Circuit Judge). [513530] [17-1798, 17-1799, 17-1800] [JAB] [Entered: 04/16/2018 09:54 AM] (16) |
| Feb 5, 2018 | 57 | Submitted after ORAL ARGUMENT by Christopher K. Hu for Emcure Pharmaceuticals Limited, Heritage Pharma Labs Inc., Invagen Pharmaceuticals, Inc., Teva Pharmaceutical Industries, Ltd. and Teva Pharmaceuticals USA, Inc. and Preston K Ratliff, II for Sumitomo Dainippon Pharma Co., Ltd. and Sunovion Pharmaceuticals Inc. Panel: Judge: Moore, Judge: Mayer, Judge: Stoll. [495063]--[Edited 04/16/2018 by JAB to update arguing attorney information] [SJ] [Entered: 02/05/2018 11:10 AM] (0) |
| Jan 16, 2018 | 56 | Response to oral argument order from the Appellees Sumitomo Dainippon Pharma Co., Ltd. and Sunovion Pharmaceuticals Inc.. designating Preston K. Ratliff II as arguing attorney. Designated time for argument: 15 minutes. Designated time for rebuttal: 0 minutes. Service of other counsel by Notice of Docket Activity from this entry. [489767] [Preston Ratliff] [Entered: 01/16/2018 02:13 PM] (0) |
| Jan 16, 2018 | 55 | Response to oral argument order from the Appellants Emcure Pharmaceuticals Limited, Heritage Pharma Labs Inc., Invagen Pharmaceuticals, Inc., Teva Pharmaceutical Industries, Ltd. and Teva Pharmaceuticals USA, Inc.. designating Christopher Hu as arguing attorney. Designated time for argument: 10 minutes. Designated time for rebuttal: 5 minutes. Service of other counsel by Notice of Docket Activity from this entry. [489689] [Christopher Hu] [Entered: 01/16/2018 11:46 AM] (0) |
| Dec 19, 2017 | 54 | NOTICE OF CALENDARING. Panel: 1802B. Case scheduled Feb 05, 2018 10:00 a.m. at the United States Court of Appeals for the Federal Circuit (Howard T. Markey National Courts Building, 717 Madison Place, N.W. Washington, DC 20439), Courtroom 402. Response to oral argument order due: 01/16/2018. Arguing counsel is required to check-in with the Clerk's Office, 4th Floor, Room 401, between 8:30 a.m. and 9:30 a.m. on the day of argument. Please review the Oral Argument Order. [483794] [JAB] [Entered: 12/19/2017 01:49 PM] (0) |
| Oct 25, 2017 | 53 | Notice from Appellees Sumitomo Dainippon Pharma Co., Ltd. and Sunovion Pharmaceuticals Inc. regarding conflicts with oral argument (1/8-1/12/2018, 2/9/2018, 3/5-3/9/2018, 3/12/2018). Service: 10/25/2017 by email. [470609] [Preston Ratliff] [Entered: 10/25/2017 04:45 PM] (1) |
| Oct 23, 2017 | 52 | Notice from Appellants Teva Pharmaceutical Industries, Ltd. and Teva Pharmaceuticals USA, Inc. regarding conflicts with oral argument (January 11-12, February 7-9, March 5-9, April 5-6). Service: 10/23/2017 by email. [469931] [William Jay] [Entered: 10/23/2017 04:37 PM] (2) |
| Aug 8, 2017 | 51 | Notice from Appellees Sumitomo Dainippon Pharma Co., Ltd. and Sunovion Pharmaceuticals Inc. regarding conflicts with oral argument (October 2-6, November 8, 2017). Service: 08/08/2017 by email. [452161] [Preston Ratliff] [Entered: 08/08/2017 12:25 PM] (1) |
| Aug 8, 2017 | 50 | Notice from Appellants Teva Pharmaceutical Industries, Ltd. and Teva Pharmaceuticals USA, Inc. regarding conflicts with oral argument (October 2,4-6 and December 7-8). Service: 08/08/2017 by email. [452077] [Ira Levy] [Entered: 08/08/2017 11:11 AM] (2) |
| Aug 1, 2017 | 48 | 6 paper copies of the appendix Brief [46] received from Appellants Emcure Pharmaceuticals Limited, Heritage Pharma Labs Inc., Invagen Pharmaceuticals, Inc., Teva Pharmaceutical Industries, Ltd. and Teva Pharmaceuticals USA, Inc.. [450804] [FMS] [Entered: 08/02/2017 08:56 AM] (0) |
| Aug 1, 2017 | 47 | Pursuant to Practice Note 34, counsel should advise the clerk of court of scheduling conflicts for the next three court weeks, or thereafter. When filing the notice of conflicts, counsel should docket the Notice Regarding Conflicts with Argument Dates event, which is found in the Calendar event category. The notice of conflict with oral argument is due on or before 08/08/2017. [450568] [FMS] [Entered: 08/01/2017 09:37 AM] (0) |
| Jul 31, 2017 | 49 | 6 paper copies of the Reply Brief [42] received from Appellants Emcure Pharmaceuticals Limited, Heritage Pharma Labs Inc., Invagen Pharmaceuticals, Inc., Teva Pharmaceutical Industries, Ltd. and Teva Pharmaceuticals USA, Inc.. [450810] [FMS] [Entered: 08/02/2017 09:03 AM] (0) |
| Jul 31, 2017 | 46 | APPENDIX FILED for Emcure Pharmaceuticals Limited, Heritage Pharma Labs Inc., Invagen Pharmaceuticals, Inc., Teva Pharmaceutical Industries, Ltd. and Teva Pharmaceuticals USA, Inc. [43]. Number of Pages: 290. Service: 07/31/2017 by email. The paper copies of the brief should be received by the court on or before 08/08/2017. [450567] [FMS] [Entered: 08/01/2017 09:36 AM] (290) |
| Jul 31, 2017 | 45 | Certificate of Compliance with Fed. Cir. R. 11(d) (Trial Court) for Appellants Emcure Pharmaceuticals Limited, Heritage Pharma Labs Inc., Invagen Pharmaceuticals, Inc., Teva Pharmaceutical Industries, Ltd. and Teva Pharmaceuticals USA, Inc.. Service: 07/31/2017 by email. [450480] [Robert Silver] [Entered: 07/31/2017 05:00 PM] (4) |
| Jul 31, 2017 | 44 | Statement of Compliance with Fed. Cir. R. 33 for Appellants Emcure Pharmaceuticals Limited, Heritage Pharma Labs Inc., Invagen Pharmaceuticals, Inc., Teva Pharmaceutical Industries, Ltd., Teva Pharmaceuticals USA, Inc. and Appellees Sumitomo Dainippon Pharma Co., Ltd. and Sunovion Pharmaceuticals Inc.. Service: 07/31/2017 by email. [450458] [Robert Silver] [Entered: 07/31/2017 04:08 PM] (5) |
| Jul 31, 2017 | 43 | TENDERED from Appellants Emcure Pharmaceuticals Limited, Heritage Pharma Labs Inc., Invagen Pharmaceuticals, Inc., Teva Pharmaceutical Industries, Ltd., Teva Pharmaceuticals USA, Inc. and Appellees Sumitomo Dainippon Pharma Co., Ltd. and Sunovion Pharmaceuticals Inc.. Title: JOINT APPENDIX. Service: 07/31/2017 by email. [450455] [Robert Silver] [Entered: 07/31/2017 04:06 PM] (290) |
| Jul 24, 2017 | 42 | REPLY BRIEF FILED for Appellants Emcure Pharmaceuticals Limited, Heritage Pharma Labs Inc., Invagen Pharmaceuticals, Inc., Teva Pharmaceutical Industries, Ltd. and Teva Pharmaceuticals USA, Inc. [41]. Number of Pages: 20. Service: 07/24/2017 by email. The paper copies of the brief should be received by the court on or before 08/02/2017. Appendix is due 07/31/2017. [449294] [FMS] [Entered: 07/26/2017 09:49 AM] (31) |
| Jul 24, 2017 | 41 | TENDERED from Appellants Emcure Pharmaceuticals Limited, Heritage Pharma Labs Inc., Invagen Pharmaceuticals, Inc., Teva Pharmaceutical Industries, Ltd. and Teva Pharmaceuticals USA, Inc.. Title: REPLY BRIEF. Service: 07/24/2017 by email. [448853] [Ira Levy] [Entered: 07/24/2017 08:31 PM] (31) |
| Jul 21, 2017 | 40 | Entry of appearance for David J. Zimmer as of counsel for Appellants Teva Pharmaceutical Industries, Ltd. and Teva Pharmaceuticals USA, Inc.. Service: 07/21/2017 by email. [448352] [David Zimmer] [Entered: 07/21/2017 01:41 PM] (2) |
| Jul 3, 2017 | 39 | **TEXT ONLY** ORDER granting motion to extend time to file reply brief [38] filed by Appellants Teva Pharmaceutical Industries, Ltd. and Teva Pharmaceuticals USA, Inc. Reply brief is due 07/24/2017. Service as of this date by Clerk of Court. This order has been issued without an attached document and is official and binding. [443880] [FMS] [Entered: 07/03/2017 01:56 PM] (0) |
| Jun 30, 2017 | 38 | MOTION of Appellants Teva Pharmaceutical Industries, Ltd. and Teva Pharmaceuticals USA, Inc. to extend the time to 07/24/2017 at 11:59 pm to file the reply brief. Any response is due within 10 days of service [Consent: unopposed]. Service: 06/30/2017 by email. [443671] [Ira Levy] [Entered: 06/30/2017 05:32 PM] (10) |
| Jun 30, 2017 | 37 | 6 paper copies of the Opening Response Brief [36] received from Appellees Sumitomo Dainippon Pharma Co., Ltd. and Sunovion Pharmaceuticals Inc. [443366] [CW] [Entered: 06/30/2017 10:13 AM] (0) |
| Jun 26, 2017 | 36 | BRIEF FILED for Appellees Sumitomo Dainippon Pharma Co., Ltd. and Sunovion Pharmaceuticals Inc. [35]. Number of Pages: 34. Service: 06/26/2017 by email. The paper copies of the brief should be received by the court on or before 07/05/2017. Appellants Emcure Pharmaceuticals Limited, Heritage Pharma Labs Inc., Invagen Pharmaceuticals, Inc., Teva Pharmaceutical Industries, Ltd. and Teva Pharmaceuticals USA, Inc. reply brief is due 07/13/2017. [442473] [FMS] [Entered: 06/27/2017 02:26 PM] (41) |
| Jun 26, 2017 | 35 | TENDERED from Appellees Sumitomo Dainippon Pharma Co., Ltd. and Sunovion Pharmaceuticals Inc.. Title: OPENING BRIEF. Service: 06/26/2017 by email. [442241] [Preston Ratliff] [Entered: 06/26/2017 11:36 PM] (41) |
| May 18, 2017 | 34 | 6 paper copies of the Opening Brief [32] received from Appellants Emcure Pharmaceuticals Limited, Heritage Pharma Labs Inc., etc. [432557] [KW] [Entered: 05/18/2017 01:49 PM] (0) |
| May 17, 2017 | 33 | CLERK'S OFFICE QUALITY CONTROL MESSAGE: Notice regarding the ECF account of Mr. Preston K Ratliff, II for Sumitomo Dainippon Pharma Co., Ltd. and Sunovion Pharmaceuticals Inc. The e-mail address, (petercsepes@paulhastings.com), associated with your CM/ECF account has generated a delivery failure notice. Counsel should promptly report a change in contact information with the Pacer Service Center (see Fed. Cir. R. 47.3(c)(1). [432122] [PMM] [Entered: 05/17/2017 09:44 AM] (0) |
| May 15, 2017 | 31 | TENDERED from Appellants Emcure Pharmaceuticals Limited, Heritage Pharma Labs Inc., Invagen Pharmaceuticals, Inc., Teva Pharmaceutical Industries, Ltd. and Teva Pharmaceuticals USA, Inc.. Title: OPENING BRIEF. Service: 05/15/2017 by email. [431586] [Ira Levy] [Entered: 05/15/2017 05:04 PM] (121) |
| May 15, 2017 | 32 | BRIEF FILED for Appellants Emcure Pharmaceuticals Limited, Heritage Pharma Labs Inc., Invagen Pharmaceuticals, Inc., Teva Pharmaceutical Industries, Ltd. and Teva Pharmaceuticals USA, Inc. [31]. Number of Pages: 38. Service: 05/15/2017 by email. The paper copies of the brief should be received by the court on or before 05/23/2017. Appellees Sumitomo Dainippon Pharma Co., Ltd. and Sunovion Pharmaceuticals Inc. brief is due 06/26/2017. [431665] [JCA] [Entered: 05/16/2017 08:47 AM] (121) |
| Apr 25, 2017 | 30 | Entry of appearance for David C. Kistler as of counsel for Appellants Emcure Pharmaceuticals Limited and Heritage Pharma Labs Inc.. Service: 04/25/2017 by email. [426808] [David Kistler] [Entered: 04/25/2017 10:05 AM] (2) |
| Apr 25, 2017 | 29 | REMINDER: All counsel of record are reminded of their responsibility per Fed. Cir. R. 47.4(a)and Fed. Cir. R. 47.3 to promptly submit an amended Certificate of Interest (COI) and/or Entry of Appearance (EOA) as information changes during the pendency of the appeal. Failure to comply with these Rules may delay the timely processing of your case or result in adverse action. [426769] [JCA] [Entered: 04/25/2017 09:02 AM] (0) |
| Mar 30, 2017 | 28 | Entry of appearance for William C. Baton as of counsel for Appellees Sumitomo Dainippon Pharma Co., Ltd. and Sunovion Pharmaceuticals Inc.. Service: 03/30/2017 by email, clerk. [420497] [William Baton] [Entered: 03/30/2017 05:04 PM] (3) |
| Mar 30, 2017 | 27 | Entry of appearance for Charles M. Lizza as of counsel for Appellees Sumitomo Dainippon Pharma Co., Ltd. and Sunovion Pharmaceuticals Inc.. Service: 03/30/2017 by email, clerk. [420494] [Charles Lizza] [Entered: 03/30/2017 05:00 PM] (3) |
| Mar 30, 2017 | 26 | Entry of appearance for Stephen B. Kinnaird as of counsel for Appellees Sumitomo Dainippon Pharma Co., Ltd. and Sunovion Pharmaceuticals Inc.. Service: 03/30/2017 by email, clerk. [420493] [Stephen Kinnaird] [Entered: 03/30/2017 04:57 PM] (3) |
| Mar 30, 2017 | 25 | Entry of appearance for Joseph M. O'Malley, Jr. as of counsel for Appellees Sumitomo Dainippon Pharma Co., Ltd. and Sunovion Pharmaceuticals Inc.. Service: 03/30/2017 by email, clerk. [420492] [Joseph O'Malley] [Entered: 03/30/2017 04:53 PM] (3) |
| Mar 30, 2017 | 24 | Docketing Statement for the Appellees Sumitomo Dainippon Pharma Co., Ltd. and Sunovion Pharmaceuticals Inc.. Service: 03/30/2017 by email, clerk. [420488] [Preston Ratliff] [Entered: 03/30/2017 04:49 PM] (5) |
| Mar 30, 2017 | 23 | Certificate of Interest for the Appellees Sumitomo Dainippon Pharma Co., Ltd. and Sunovion Pharmaceuticals Inc.. Service: 03/30/2017 by email, clerk. [420486] [Preston Ratliff] [Entered: 03/30/2017 04:46 PM] (4) |
| Mar 30, 2017 | 22 | Entry of appearance for Preston K. Ratliff II as principal counsel for Appellees Sumitomo Dainippon Pharma Co., Ltd. and Sunovion Pharmaceuticals Inc.. Service: 03/30/2017 by email, clerk. [420482] [Preston Ratliff] [Entered: 03/30/2017 04:44 PM] (3) |
| Mar 30, 2017 | 21 | Corrected Certificate of Interest for the Appellants Emcure Pharmaceuticals Limited and Heritage Pharma Labs Inc.. Service: 03/30/2017 by email. [420481] [Jay Lessler] [Entered: 03/30/2017 04:44 PM] (2) |
| Mar 30, 2017 | 20 | Certificate of Interest for the Appellants Teva Pharmaceutical Industries, Ltd. and Teva Pharmaceuticals USA, Inc.. Service: 03/30/2017 by email. [420463] [Ira Levy] [Entered: 03/30/2017 04:30 PM] (3) |
| Mar 30, 2017 | 19 | Docketing Statement for the Appellants Teva Pharmaceutical Industries, Ltd. and Teva Pharmaceuticals USA, Inc.. Service: 03/30/2017 by email. [420460] [Ira Levy] [Entered: 03/30/2017 04:29 PM] (3) |
| Mar 30, 2017 | 18 | Entry of appearance for Brian J. Prew as of counsel for Appellants Teva Pharmaceutical Industries, Ltd. and Teva Pharmaceuticals USA, Inc.. Service: 03/30/2017 by email. [420458] [Ira Levy] [Entered: 03/30/2017 04:28 PM] (2) |
| Mar 30, 2017 | 17 | Entry of appearance for Linnea P. Cipriano as of counsel for Appellants Teva Pharmaceutical Industries, Ltd. and Teva Pharmaceuticals USA, Inc.. Service: 03/30/2017 by email. [420455] [Ira Levy] [Entered: 03/30/2017 04:27 PM] (2) |
| Mar 30, 2017 | 16 | Entry of appearance for Cynthia Lambert Hardman as of counsel for Appellants Teva Pharmaceutical Industries, Ltd. and Teva Pharmaceuticals USA, Inc.. Service: 03/30/2017 by email. [420452] [Ira Levy] [Entered: 03/30/2017 04:25 PM] (2) |
| Mar 30, 2017 | 15 | Entry of appearance for William M. Jay as of counsel for Appellants Teva Pharmaceutical Industries, Ltd. and Teva Pharmaceuticals USA, Inc.. Service: 03/30/2017 by email. [420445] [Ira Levy] [Entered: 03/30/2017 04:23 PM] (2) |
| Mar 30, 2017 | 14 | Entry of appearance for Ira J. Levy as principal counsel for Appellants Teva Pharmaceutical Industries, Ltd. and Teva Pharmaceuticals USA, Inc.. Service: 03/30/2017 by email. [420435] [Ira Levy] [Entered: 03/30/2017 04:17 PM] (2) |
| Mar 30, 2017 | 13 | NOTICE OF DEFICIENCY: The certificate of interest Document No. [5] filed by Appellants Emcure Pharmaceuticals Limited and Heritage Pharma Labs Inc. in 17-1798 is incomplete [question 2] and therefore cannot be accepted for filing at this time. Question 2 may not be left blank; if applicable, "none" may be used. You are being afforded the opportunity to correct the deficiency. At the discretion of the court, the corrected document may be accepted for filing if received before midnight (EST) on the date of this notice. [420431] [CMP] [Entered: 03/30/2017 04:15 PM] (0) |
| Mar 30, 2017 | 12 | Entry of appearance for Pei-Ru Wey as of counsel for Appellant Invagen Pharmaceuticals, Inc.. Service: 03/30/2017 by email. [420411] [Pei-Ru Wey] [Entered: 03/30/2017 03:57 PM] (3) |
| Mar 30, 2017 | 11 | Entry of appearance for Salvatore Guerriero as of counsel for Appellant Invagen Pharmaceuticals, Inc.. Service: 03/30/2017 by email. [420399] [Salvatore Guerriero] [Entered: 03/30/2017 03:45 PM] (3) |
| Mar 30, 2017 | 10 | Docketing Statement for the Appellant Invagen Pharmaceuticals, Inc.. Service: 03/30/2017 by email. [420395] [Robert Silver] [Entered: 03/30/2017 03:41 PM] (5) |
| Mar 30, 2017 | 9 | Certificate of Interest for the Appellant Invagen Pharmaceuticals, Inc.. Service: 03/30/2017 by email. [420392] [Robert Silver] [Entered: 03/30/2017 03:40 PM] (3) |
| Mar 30, 2017 | 8 | Entry of appearance for Robert S. Silver as principal counsel for Appellant Invagen Pharmaceuticals, Inc.. Service: 03/30/2017 by email. [420390] [Robert Silver] [Entered: 03/30/2017 03:39 PM] (3) |
| Mar 30, 2017 | 7 | Entry of appearance for Christopher K. Hu as of counsel for Appellants Emcure Pharmaceuticals Limited and Heritage Pharma Labs Inc.. Service: 03/30/2017 by email. [420381] [Christopher Hu] [Entered: 03/30/2017 03:29 PM] (2) |
| Mar 30, 2017 | 6 | Docketing Statement for the Appellants Emcure Pharmaceuticals Limited and Heritage Pharma Labs Inc.. Service: 03/30/2017 by email. [420380] [Jay Lessler] [Entered: 03/30/2017 03:25 PM] (4) |
| Mar 30, 2017 | 5 | Certificate of Interest for the Appellants Emcure Pharmaceuticals Limited and Heritage Pharma Labs Inc.. Service: 03/30/2017 by email. [420375] [Jay Lessler] [Entered: 03/30/2017 03:23 PM] (0) |
| Mar 30, 2017 | 4 | Entry of appearance for Jay P. Lessler as principal counsel for Appellants Emcure Pharmaceuticals Limited and Heritage Pharma Labs Inc.. Service: 03/30/2017 by email. [420371] [Jay Lessler] [Entered: 03/30/2017 03:22 PM] (2) |
| Mar 23, 2017 | 3 | Transcript Purchase Order Form for the Appellants Emcure Pharmaceuticals Limited, Heritage Pharma Labs Inc., Invagen Pharmaceuticals, Inc., Teva Pharmaceutical Industries, Ltd. and Teva Pharmaceuticals USA, Inc. indicating that a transcript is not needed for the appeal. Service: 03/23/2017 by email. [418562] [Ira Levy] [Entered: 03/23/2017 06:28 PM] (6) |
| Mar 16, 2017 | 2 | Note to file: The following cases are associated:17-1798 Lead with 17-1799, 17-1800 Consolidated. FURTHER ENTRIES WILL BE ADDED TO THE LEAD APPEAL ONLY. [415986] [17-1798, 17-1799, 17-1800] [JCA] [Entered: 03/16/2017 09:10 AM] (0) |
| Mar 16, 2017 | 1 | Appeal docketed. Received: 03/13/2017. [415977]Entry of Appearance due 03/30/2017. Certificate of Interest is due on 03/30/2017. Docketing Statement due 03/30/2017. Appellant/Petitioner's brief is due 05/15/2017. [JCA] [Entered: 03/16/2017 08:59 AM] (36) |
